Experienced in Heart Failure with Preserved Ejection Fraction (HFpEF)

Dr. Ahmad A. Haidar

Internal Medicine
Curana Health Of Mississippi LLC
232 Market St, 
Flowood, MS 
Accepting New Patients
Offers Telehealth
Experienced in Heart Failure with Preserved Ejection Fraction (HFpEF)
Curana Health Of Mississippi LLC
232 Market St, 
Flowood, MS 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Ahmad Haidar is a primary care provider, practicing in Internal Medicine in Flowood, Mississippi. Dr. Haidar is rated as an Experienced provider by MediFind in the treatment of Heart Failure with Preserved Ejection Fraction (HFpEF). His top areas of expertise are Type 1 Diabetes (T1D), Low Blood Sugar, Hypertension, Glucocorticoid-Remediable Aldosteronism, and Hormone Replacement Therapy (HRT). Dr. Haidar is currently accepting new patients.

His clinical research consists of co-authoring 72 peer reviewed articles and participating in 12 clinical trials. MediFind looks at clinical research from the past 15 years.

Specialties
Internal Medicine
Licenses
Internal Medicine in MS
Hospital Affiliations
Highland Community Hospital
Slidell Memorial Hospital
Languages Spoken
English
Gender
Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Anthem
  • EPO
  • HMO
  • POS
  • PPO
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
Cambia Health Solutions
  • EPO
  • INSURANCE PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • PPO
Change Healthcare
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
Cigna
  • EPO
  • HMO
  • PPO
Devoted Health
  • MEDICARE MAPD
  • OTHER MEDICARE
Health Care Services Corporation
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
Highmark
  • EPO
  • HMO
  • PPO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Louisiana Healthcare Connections
  • HMO
  • MANAGED MEDICAID PLAN
Magnolia Health
  • HMO
Managed Medicaid
  • OTHER MANAGED MEDICAID
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
Medicare
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE PART D
Premera Blue Cross
  • INSURANCE PLAN
  • MEDICARE MAPD
  • OTHER COMMERCIAL
  • PPO
Primewell Health Services
  • HMO
  • MEDICARE MAPD
  • MEDICARE SNP
  • OTHER MEDICARE PART D
  • POS
TeamCare
  • OTHER COMMERCIAL
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Walgreens
  • MEDICARE DISCOUNT CARD
  • MEDICARE PDP
  • OTHER MEDICARE
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 16 Less Insurance Carriers -

Locations

CURANA HEALTH OF MISSISSIPPI LLC
232 Market St, Flowood, MS 39232
Other Locations
200 Golf Course Dr, Carriere, MS 39426

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

12 Clinical Trials

An Open-Label, Randomized, Two-Way, Parallel Study to Compare the Effectiveness of Multiple Daily Injection Treatment With an Insulin Dose Optimization Algorithm in Free-Living Outpatient Conditions in Patients With Type 1 Diabetes
An Open-Label, Randomized, Two-Way, Parallel Study to Compare the Effectiveness of Multiple Daily Injection Treatment With an Insulin Dose Optimization Algorithm in Free-Living Outpatient Conditions in Patients With Type 1 Diabetes
Enrollment Status: Completed
Publish Date: May 16, 2024
Intervention Type: Device
Study Phase: Not Applicable
A Single Arm Pilot Study to Assess the Feasibility of a Learning Algorithm to Automatically Adjust Basal and Bolus Recommendations for High Fat Meals and Exercise Management for Individuals With Type 1 Diabetes on MDI Therapy
A Single Arm Pilot Study to Assess the Feasibility of a Learning Algorithm to Automatically Adjust Basal and Bolus Recommendations for High Fat Meals and Exercise Management for Individuals With Type 1 Diabetes on MDI Therapy
Enrollment Status: Completed
Publish Date: November 09, 2023
Intervention Type: Device
Study Phase: Not Applicable
A Randomized, Controlled, Crossover Pilot Trial to Assess a Fully Automated, Dual-hormone (Insulin-and-pramlintide) Artificial Pancreas Without Carbohydrate Counting in Regulating Glucose Levels in Adults With Type 1 Diabetes
A Randomized, Controlled, Crossover Pilot Trial to Assess a Fully Automated, Dual-hormone (Insulin-and-pramlintide) Artificial Pancreas Without Carbohydrate Counting in Regulating Glucose Levels in Adults With Type 1 Diabetes
Enrollment Status: Completed
Publish Date: October 25, 2023
Intervention Type: Device, Drug
Study Phase: Not Applicable
A Pilot Study to Assess Closed-loop Insulin Delivery to Regulate Glucose Levels in Children With Type 1 Diabetes in Outpatient Free-living Settings.
A Pilot Study to Assess Closed-loop Insulin Delivery to Regulate Glucose Levels in Children With Type 1 Diabetes in Outpatient Free-living Settings.
Enrollment Status: Terminated
Publish Date: July 12, 2023
Intervention Type: Other
Study Phase: Not Applicable
The Effect of Low-dose Empagliflozin on Glucose Control in Adult Patients With Type 1 Diabetes on a Closed-loop Insulin System: a Randomized Cross-over Controlled Trial
The Effect of Low-dose Empagliflozin on Glucose Control in Adult Patients With Type 1 Diabetes on a Closed-loop Insulin System: a Randomized Cross-over Controlled Trial
Enrollment Status: Completed
Publish Date: October 12, 2022
Intervention Type: Drug
Study Drug: Empagliflozin
Study Phase: Phase 1
Alleviating Carbohydrate Counting for Patients With Type 1 Diabetes Using a Novel Insulin-plus-pramlintide Artificial Pancreas: a Randomized Controlled Crossover Trial.
Alleviating Carbohydrate Counting for Patients With Type 1 Diabetes Using a Novel Insulin-plus-pramlintide Artificial Pancreas: a Randomized Controlled Crossover Trial.
Enrollment Status: Completed
Publish Date: October 10, 2022
Intervention Type: Drug, Device
Study Phase: Not Applicable
Effect of SGLT2 Inhibition on Improving the Glycemic Performance of the Single Hormone Artificial Pancreas Configuration in Type 1 Diabetes in the Outpatient Setting - A Randomized Placebo Controlled Cross-Over Multicentre Clinical Trial
Effect of SGLT2 Inhibition on Improving the Glycemic Performance of the Single Hormone Artificial Pancreas Configuration in Type 1 Diabetes in the Outpatient Setting - A Randomized Placebo Controlled Cross-Over Multicentre Clinical Trial
Enrollment Status: Completed
Publish Date: June 07, 2022
Intervention Type: Drug, Device
Study Drug: Empagliflozin
Study Phase: Phase 3
Alleviating Carbohydrate-Counting Burden in Type 1 Diabetes Using Artificial Pancreas and Sodium Glucose-Linked Transporter 2 Inhibition: A Randomized Open-Label Crossover Trial.
Alleviating Carbohydrate-Counting Burden in Type 1 Diabetes Using Artificial Pancreas and Sodium Glucose-Linked Transporter 2 Inhibition: A Randomized Open-Label Crossover Trial.
Enrollment Status: Completed
Publish Date: June 24, 2021
Intervention Type: Device, Drug, Behavioral
Study Phase: Not Applicable
A Randomized, Controlled, Crossover Trial to Assess a Dual-hormone (Insulin-pramlintide) Closed-loop Delivery Without Carbohydrate Counting in Regulating Glucose Levels in Adults With Type 1 Diabetes
A Randomized, Controlled, Crossover Trial to Assess a Dual-hormone (Insulin-pramlintide) Closed-loop Delivery Without Carbohydrate Counting in Regulating Glucose Levels in Adults With Type 1 Diabetes
Enrollment Status: Completed
Publish Date: June 08, 2021
Intervention Type: Drug
Study Phase: Phase 2
A Preliminary Pilot Study to Assess Insulin-plus-Pramlintide Closed-loop Delivery System in Pump Treated Patients With Type 1 Diabetes Mellitus
A Preliminary Pilot Study to Assess Insulin-plus-Pramlintide Closed-loop Delivery System in Pump Treated Patients With Type 1 Diabetes Mellitus
Enrollment Status: Completed
Publish Date: April 01, 2021
Intervention Type: Device, Combination product
Study Phase: Not Applicable
An Open-label, Randomized, Three-way, Crossover Study to Assess the Safety and Efficacy of Closed-loop Delivery With and Without Meal Detection Module and Conventional Pump Therapy in Regulating Glucose Levels After a Missed Bolus in Adolescents With Type 1 Diabetes in Inpatient Settings
An Open-label, Randomized, Three-way, Crossover Study to Assess the Safety and Efficacy of Closed-loop Delivery With and Without Meal Detection Module and Conventional Pump Therapy in Regulating Glucose Levels After a Missed Bolus in Adolescents With Type 1 Diabetes in Inpatient Settings
Enrollment Status: Completed
Publish Date: May 27, 2020
Intervention Type: Device
Study Phase: Not Applicable
A Randomized, Three-way, Crossover Study to Assess the Efficacy of Fast-acting Insulin-plus-pramlintide Closed-loop Co-administration, Regular Insulin-plus-pramlintide Closed-loop Co-administration, and Fast-acting Insulin-alone Closed-loop Infusion in Regulating Glucose Levels Over a 24-hour Period in Adults With Type 1 Diabetes in Inpatient Settings.
A Randomized, Three-way, Crossover Study to Assess the Efficacy of Fast-acting Insulin-plus-pramlintide Closed-loop Co-administration, Regular Insulin-plus-pramlintide Closed-loop Co-administration, and Fast-acting Insulin-alone Closed-loop Infusion in Regulating Glucose Levels Over a 24-hour Period in Adults With Type 1 Diabetes in Inpatient Settings.
Enrollment Status: Completed
Publish Date: February 17, 2020
Intervention Type: Other
Study Phase: Phase 2
View 11 Less Clinical Trials

72 Total Publications

Semaglutide withdrawal in adults with type 1 diabetes on pump therapy: A post-hoc analysis from a double-blinded randomized controlled trial.
Semaglutide withdrawal in adults with type 1 diabetes on pump therapy: A post-hoc analysis from a double-blinded randomized controlled trial.
Journal: Diabetes, obesity & metabolism
Published: August 12, 2025
Similar Doctors
Advanced in Heart Failure with Preserved Ejection Fraction (HFpEF)
Dr. Jinna M. Shepherd
Internal Medicine
Advanced in Heart Failure with Preserved Ejection Fraction (HFpEF)
Dr. Jinna M. Shepherd
Internal Medicine

Rh Mississippi Hospitalist Medicine LLC

969 Lakeland Dr, 
Jackson, MS 
 (5.7 miles away)
601-200-2000
Languages Spoken:
English
See accepted insurances
Accepting New Patients

Jinna Shepherd is a primary care provider, practicing in Internal Medicine in Jackson, Mississippi. Dr. Shepherd is rated as an Advanced provider by MediFind in the treatment of Heart Failure with Preserved Ejection Fraction (HFpEF). Her top areas of expertise are Necrosis, Heart Failure with Preserved Ejection Fraction (HFpEF), Pleurisy, Pacemaker Implantation, and Gastrostomy. Dr. Shepherd is currently accepting new patients in some locations.

Advanced in Heart Failure with Preserved Ejection Fraction (HFpEF)
Dr. Zina D. Lee
Internal Medicine
Advanced in Heart Failure with Preserved Ejection Fraction (HFpEF)
Dr. Zina D. Lee
Internal Medicine

Medical Foundation Of Central Mississippi Inc

1225 N State St, 
Jackson, MS 
 (6.7 miles away)
601-292-4261
Languages Spoken:
English
See accepted insurances
Accepting New Patients

Zina Lee is a primary care provider, practicing in Internal Medicine in Jackson, Mississippi. Dr. Lee is rated as an Advanced provider by MediFind in the treatment of Heart Failure with Preserved Ejection Fraction (HFpEF). Her top areas of expertise are Heart Failure with Preserved Ejection Fraction (HFpEF), Neurotoxicity Syndromes, Ogilvie Syndrome, Hip Replacement, and Endoscopy. Dr. Lee is currently accepting new patients.

Advanced in Heart Failure with Preserved Ejection Fraction (HFpEF)
Dr. Lucius F. Sams
Internal Medicine
Advanced in Heart Failure with Preserved Ejection Fraction (HFpEF)
Dr. Lucius F. Sams
Internal Medicine

Medical Foundation Of Central Mississippi Inc

3011 Greenfield Rd, 
Pearl, MS 
 (5.0 miles away)
601-825-9000
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Lucius Sams is a primary care provider, practicing in Internal Medicine in Pearl, Mississippi. Dr. Sams is rated as a Distinguished provider by MediFind in the treatment of Heart Failure with Preserved Ejection Fraction (HFpEF). His top areas of expertise are Familial Hypertension, Glucocorticoid-Remediable Aldosteronism, Hypertension, and Low Potassium Level. Dr. Sams is currently accepting new patients.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Haidar's expertise for a condition
ConditionClose
View All 23 Advanced Conditions
View All 121 Experienced Conditions
Want to save this doctor for later?
Sign Up
Is this your doctor?
Find A Second Opinion
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile